Abbott Laboratories (NYSE:ABT) Stock Sale Reported by Rep. Pete Sessions

Representative Pete Sessions (Republican-Texas) recently sold shares of Abbott Laboratories (NYSE:ABT). In a filing disclosed on October 27th, the Representative disclosed that they had sold between $50,001 and $100,000 in Abbott Laboratories stock on October 2nd. The trade occurred in the Representative’s “TRUST ONE” account.

Representative Pete Sessions also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Walt Disney (NYSE:DIS) on 10/28/2026.
• Sold $15,001 – $50,000 in shares of Amazon.com (NASDAQ:AMZN) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of McDonald’s (NYSE:MCD) on 10/27/2026.
• Sold $15,001 – $50,000 in shares of Lowe’s Companies (NYSE:LOW) on 10/22/2026.
• Sold $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 10/22/2026.
• Sold $1,001 – $15,000 in shares of Solstice Advanced Mat (NASDAQ:SOLS) on 10/21/2026.
• Sold $1,001 – $15,000 in shares of PepsiCo (NASDAQ:PEP) on 10/21/2026.
• Sold $0 – $1,000 in shares of Resideo Technologies (NYSE:REZI) on 10/21/2026.
• Sold $1,001 – $15,000 in shares of International Business Machines (NYSE:IBM) on 10/20/2026.
• Sold $15,001 – $50,000 in shares of Berkshire Hathaway (NYSE:BRK.B) on 10/15/2026.

Abbott Laboratories Price Performance

NYSE ABT opened at $104.37 on Friday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38. The firm’s 50 day moving average price is $104.52 and its 200-day moving average price is $102.15. Abbott Laboratories has a 52-week low of $81.97 and a 52-week high of $132.02. The company has a market cap of $180.60 billion, a PE ratio of 19.08, a P/E/G ratio of 1.80 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Wednesday, October 21st. The healthcare product maker reported $1.42 EPS for the quarter, hitting analysts’ consensus estimates of $1.42. The company had revenue of $13.01 billion during the quarter, compared to the consensus estimate of $12.99 billion. Abbott Laboratories had a net margin of 9.75% and a return on equity of 17.97%. Abbott Laboratories’s revenue for the quarter was up 14.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.30 earnings per share. Sell-side analysts forecast that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be given a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 2.4%. The ex-dividend date of this dividend is Thursday, October 15th. Abbott Laboratories’s dividend payout ratio is presently 94.03%.

Institutional Investors Weigh In On Abbott Laboratories

Several hedge funds have recently added to or reduced their stakes in ABT. Elwood & Goetz Wealth Advisory Group LLC increased its holdings in shares of Abbott Laboratories by 3.1% in the third quarter. Elwood & Goetz Wealth Advisory Group LLC now owns 3,216 shares of the healthcare product maker’s stock valued at $318,000 after purchasing an additional 97 shares during the last quarter. Parkway Wealth Management Group LLC lifted its holdings in shares of Abbott Laboratories by 3.2% in the 3rd quarter. Parkway Wealth Management Group LLC now owns 3,208 shares of the healthcare product maker’s stock worth $317,000 after acquiring an additional 98 shares during the last quarter. Signature Equity Partners LLC boosted its position in shares of Abbott Laboratories by 7.9% during the third quarter. Signature Equity Partners LLC now owns 1,363 shares of the healthcare product maker’s stock worth $135,000 after buying an additional 100 shares during the period. St. Johns Investment Management Company LLC increased its stake in Abbott Laboratories by 1.0% during the second quarter. St. Johns Investment Management Company LLC now owns 9,859 shares of the healthcare product maker’s stock worth $895,000 after purchasing an additional 101 shares during the period. Finally, AA Financial Advisors LLC lifted its holdings in Abbott Laboratories by 1.7% during the 3rd quarter. AA Financial Advisors LLC now owns 6,186 shares of the healthcare product maker’s stock worth $611,000 after buying an additional 101 shares in the last quarter. 75.18% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on ABT shares. Citigroup decreased their price objective on Abbott Laboratories from $125.00 to $122.00 and set a “buy” rating for the company in a research note on Thursday, October 22nd. Wells Fargo & Company boosted their target price on shares of Abbott Laboratories from $112.00 to $119.00 and gave the stock an “overweight” rating in a report on Thursday, October 22nd. Piper Sandler restated an “overweight” rating and issued a $118.00 price target (up from $115.00) on shares of Abbott Laboratories in a report on Friday, July 17th. JPMorgan Chase & Co. reduced their price objective on shares of Abbott Laboratories from $120.00 to $118.00 and set an “overweight” rating for the company in a research note on Thursday, October 22nd. Finally, Argus cut shares of Abbott Laboratories from a “buy” rating to a “hold” rating in a research report on Tuesday. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $118.32.

Abbott Laboratories News Roundup

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott initiated the pivotal CROWN-MV trial for its investigational Cephea™ Mitral Valve System. The minimally invasive device targets symptomatic mitral valve disease patients who are not eligible for surgery or existing transcatheter repair, creating a potential future growth opportunity in structural heart care. However, the device remains investigational and commercialization is still dependent on trial results and regulatory approval. Abbott initiates pivotal trial for Cephea device
• Positive Sentiment: The company launched a next-generation Oncodetect test designed to detect residual cancer disease. The release reinforces Abbott’s diagnostics pipeline and could support longer-term growth if the test gains clinical adoption. Abbott launches next-generation Oncodetect test
• Positive Sentiment: Abbott reportedly received approximately $23.9 million in net ETF buying, indicating some institutional demand for the shares, although ETF flows are not a measure of operating performance. Abbott sees net ETF buying
• Neutral Sentiment: Abbott’s planned separation of its roughly $8.5 billion Nutrition business could allow management to focus more closely on medical devices, diagnostics and pharmaceuticals, but it would also remove a sizable source of revenue diversification. The transaction remains subject to regulatory and internal approvals. Potential Abbott Nutrition spin-off
• Neutral Sentiment: Industry reports project growth in South and Central American point-of-care diagnostics and European medical foods, markets in which Abbott participates. These reports provide favorable demand context but do not represent new company-specific contracts or guidance.
• Negative Sentiment: Argus Research downgraded Abbott from Buy to Hold, potentially limiting near-term upside and signaling a less favorable risk-reward assessment. Argus downgrades Abbott to Hold

About Representative Sessions

Pete Sessions (Republican Party) is a member of the U.S. House, representing Texas’ 17th Congressional District. He assumed office on January 3, 2021. His current term ends on January 3, 2027.

Sessions (Republican Party) ran for re-election to the U.S. House to represent Texas’ 17th Congressional District. He won in the general election on November 5, 2024.

On October 20, 2023, Sessions announced he was running to replace Kevin McCarthy (R) as speaker of the U.S. House in the 118th Congress. Sessions lost the first round of nomination voting on October 24, 2023.

Pete Sessions was born and lives in Waco, Texas. Sessions earned a B.S. from Southwestern University in 1978. Sessions’ career experience includes working as an executive with AT&T.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company that develops, manufactures and markets a broad range of medical products and services. Founded in 1888 by Wallace C. Abbott, the company is headquartered in Abbott Park, Illinois, and serves patients, healthcare providers and consumers in markets around the world.

Abbott operates across four principal businesses: medical devices, diagnostics, nutrition and established pharmaceutical products. Its offerings include glucose-monitoring systems such as FreeStyle Libre; cardiovascular devices, including stents and structural heart products; laboratory and point-of-care diagnostic systems; and branded generic medicines in areas such as gastroenterology, women’s health and cardiometabolic care.

The company’s nutrition portfolio includes infant and pediatric products such as Similac and PediaSure, adult nutritional products such as Ensure, and rehydration products such as Pedialyte.